COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Hemin in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00882804
Recruitment Status : Completed
First Posted : April 17, 2009
Last Update Posted : April 17, 2009
Information provided by:
Mayo Clinic

Brief Summary:
This study is being done because we want to learn if hemin can increase the production of heme oxygenase 1. Heme oxygenase 1 (HO-1) is an enzyme which protects cells from physical, chemical, and biologic stress. Hemin is produced from red blood cells and is approved by the Food and Drug Administration for treating acute porphyria, which is an inherited condition caused by an enzyme deficiency.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Hemin infusion Drug: placebo infusion Phase 1

Detailed Description:
Heme-oxygenase 1 (HO-1) degrades heme, protects cells against oxidative stress, and is beneficial in several experimental models but has not been pharmacologically activated in humans. The objectives of this study were to evaluate the effects of hemin on HO-1 activity in healthy subjects. Hemin is the most powerful inducer of HO-1. Hemin is FDA-approved to treat acute intermittent porphyria. In addition, hemin has also been used to treat thalassemia intermedia, myelodysplastic syndrome, and to control liver allograft failure due to recurrence of erythropoietic prototheria. Our hypothesis is that compared to placebo, hemin will increase HO-1 in humans. Ten healthy subjects will be randomized to hemin (n = 5, Panhematin®, Ovation Pharmaceuticals, 3 mg/kg i.v. in 25% albumin) or placebo (n = 5, 25% albumin) infusion. HO-1 activity will be assessed before and after (4, 6, 24, and 48 hours) infusions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Official Title: Effect of Hemin on Heme-Oxygenase-1 Activity in Healthy Subjects
Study Start Date : February 2009
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Hemin

Arm Intervention/treatment
Experimental: Hemin Drug: Hemin infusion
Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in ~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.

Placebo Comparator: placebo Drug: placebo infusion
25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.

Primary Outcome Measures :
  1. Venous carboxyhemoglobin concentrations [ Time Frame: at 6 hours ]
  2. HO-1 protein concentration in leukocytes from venous blood [ Time Frame: at 6 hours ]
  3. Serum bilirubin [ Time Frame: at 6 hours ]

Secondary Outcome Measures :
  1. Venous carboxyhemoglobin concentrations [ Time Frame: at 4, 24, and 48 hours ]
  2. HO-1 activity in leukocytes from venous blood [ Time Frame: at 4, 24, and 48 hours ]
  3. Serum bilirubin [ Time Frame: at 4, 24, and 48 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
  1. Healthy non pregnant not breast feeding, and non-smoking subjects aged 18 - 65 years old without clinical evidence of significant cardiovascular, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns. No symptoms of functional GI disorder as assessed by a validated questionnaire.
  2. No medications except for stable doses of oral contraceptives or thyroid supplementation. Because ascorbic acid can induce HO-1 activity, multivitamins will need to be discontinued for 1 week before and for the duration of the study.
  3. No intolerance or allergy to eggs
  4. Able to provide written informed consent before participating in the study
  5. Able to communicate adequately with the investigator and to comply with the requirements for the entire study
  6. Screening weight < 96 kg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00882804

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Adil E Bharucha, M.D. Mayo Clinic
Layout table for additonal information
Responsible Party: Adil E. Bharucha, M.D., Mayo Clinic, Rochester Identifier: NCT00882804    
Other Study ID Numbers: 09-000230
First Posted: April 17, 2009    Key Record Dates
Last Update Posted: April 17, 2009
Last Verified: April 2009
Keywords provided by Mayo Clinic:
hemin, heme oxygenase, humans, HO-1